DataSheet_2_A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1.zip
Anaplastic meningioma is classified as a World Health Organization (WHO) grade III tumor and shows a strong tendency to recur. Although the incidence of anaplastic meningioma is low, the high rate of recurrence and death still makes treatment a challenge. A proteomics analysis was performed to investigate the differentially expressed proteins between anaplastic meningiomas and fibrous meningiomas by micro-LC-MS/MS. The key metabolic enzyme nicotinamide phosphoribosyltransferase (NAMPT) showed upregulated expression in anaplastic meningiomas. However, targeting NAMPT to treat anaplastic meningiomas has not been reported. In vitro, NAMPT inhibitor -FK866 reduced the viability of anaplastic meningiomas by inducing cell cycle arrest at the G2/M phase. Intriguingly, the NAMPT inhibitor -FK866 decreased the protein expression of immune checkpoints PD-L1 and B7-H3 by down-regulating the STAT1 and p-STAT1 expression in vitro. Furthermore, FK866 suppressed the growth of anaplastic meningiomas in an in vivo xenograft model. The expression of Ki-67 and immune checkpoint proteins (PD-L1 and B7-H3) showed significant differences between the group treated with FK866 and the control group treated with DMSO. In conclusion, the expression of NAMPT, which plays a crucial role in energy metabolism, was upregulated in anaplastic meningiomas. The NAMPT inhibitor -FK866 significantly suppressed the growth of anaplastic meningiomas in vitro and in vivo. More strikingly, FK866 potently inhibited immune checkpoint protein (PD-L1 and B7-H3) expression by regulating STAT1 in vitro and in vivo. Our results demonstrated that NAMPT inhibitors could potentially be an effective treatment method for patients suffering from anaplastic meningiomas.
History
References
- https://doi.org//10.1016/j.jocn.2014.11.022
- https://doi.org//10.1136/jnnp.2007.121582
- https://doi.org//10.3171/2010.1.JNS091114
- https://doi.org//10.3171/jns.1997.86.5.0793
- https://doi.org//10.1016/S1470-2045(16)30321-7
- https://doi.org//10.1172/jci.insight.130688
- https://doi.org//10.1002/1521-4141(200211)32%3A11<3225%3A%3AAID-IMMU3225>3.0.CO;2-L
- https://doi.org//10.1126/science.1160809
- https://doi.org//10.1038/nrc3340
- https://doi.org//10.1074/jbc.M408388200
- https://doi.org//10.1177/1178646917691938
- https://doi.org//10.1073/pnas.1610921114
- https://doi.org//10.1101/gad.305854.117
- https://doi.org//10.1038/s41556-019-0287-4
- https://doi.org//10.18632/oncotarget.20577
- https://doi.org//10.1158/1078-0432.CCR-17-2575
- https://doi.org//10.1158/0008-5472.CAN-18-3418
- https://doi.org//10.1038/onc.2010.468
- https://doi.org//10.1158/0008-5472.CAN-18-1544
- https://doi.org//10.3389/fimmu.2019.01720
- https://doi.org//10.1053/j.gastro.2018.05.024
- https://doi.org//10.1016/j.ygeno.2018.12.012
- https://doi.org//10.1016/j.ejphar.2019.172738
- https://doi.org//10.1016/j.bbrc.2015.01.111
- https://doi.org//10.1016/j.cmet.2020.10.021
- https://doi.org//10.1016/j.celrep.2017.04.031
- https://doi.org//10.1093/nar/gky869
- https://doi.org//10.1016/j.canlet.2016.05.024
- https://doi.org//10.1002/emmm.201201250
- https://doi.org//10.1126/scisignal.abc7405
- https://doi.org//10.1073/pnas.0931259100
- https://doi.org//10.1186/s40425-019-0770-2
- https://doi.org//10.1080/14728222.2018.1471137
- https://doi.org//10.1111/cas.13886
- https://doi.org//10.1016/j.gene.2018.06.021
- https://doi.org//10.3389/fonc.2018.00622
- https://doi.org//10.1016/j.ejphar.2011.11.017
- https://doi.org//10.1016/j.ccr.2006.05.025
- https://doi.org//10.1007/s00428-014-1584-8
- https://doi.org//10.1016/j.jprot.2011.11.033
- https://doi.org//10.1073/pnas.0308102100
- https://doi.org//10.1038/s41467-021-22923-5
- https://doi.org//10.1158/0008-5472.CAN-21-0525